Kanglong Chemical (03759) plans to sell its shares in Proteologix Investments and is expected to receive an initial payment of approximately US$86.821 million
Kanglong Chemical (03759) issued an announcement regarding the sale of the Group's interest in PROTEOLOGIX, INC.
Kanglong Chemical (03759) spent 128 million yuan to buy back 5.826,500 A shares on May 17
Kanglong Chemical (03759) announced that on May 17, 2024, the company spent 128 million yuan to buy back...
Kanglong Chemical (03759) will distribute the 2023 final dividend of 2 yuan for every 10 shares on July 26
Kanglong Chemical (03759) announced that the company will distribute the end of 2023 on July 26, 2024...
NOTICE OF THE ANNUAL GENERAL MEETING OF 2023
Trending Industry Today: WUXI APPTEC Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 14th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 9 constituents up and WUXI APPTEC leading Gains.$WUXI APPTE
Changes in Hong Kong stocks | CRO concept stocks had the highest increase in the new US bill introducing an 8-year exemption period, and negative risks of short-term overseas policies were implemented
The Zhitong Finance App learned that CRO concept stocks had the highest gains. As of press release, Yao Ming Kangde (02359) rose 6.28% to HK$42.3; Pharmaceutical Biotech (02269) rose 5.52% to HK$14.92; Kingsley Biotech (01548) rose 4.86% to HK$12.52; Kanglong Chemical (03759) rose 4.93% to HK$11.5. According to the news, last Friday local time, Brad R. Wenstrup, a Republican member of the US House of Representatives, initiated a new version of the Biosafety Act (H.R. 8333).
Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Kanglong Chemical (300759.SZ): Initial repurchase of 250,000 shares involving 4.9874 million yuan
Gelonghui, May 8, 丨 Kanglong Huacheng (300759.SZ) announced that on May 8, 2024, the company used its own funds to repurchase shares through centralized bidding transactions for the first time through a special stock repurchase securities account. The number of shares repurchased was 250,000 shares, accounting for 0.01% of the company's current total share capital (1,787,394,297 shares). The highest transaction price of the repurchase was 19.99 yuan/share, and the total transaction amount was 49,874.33 million yuan (excluding transaction fees).
Kanglong Chemical (03759.HK) spent 4.987 million yuan to buy back 250,000 A shares on May 8
Gelonghui, May 8, 丨 Kanglong Chemical (03759.HK) announced that it spent 4.987 million yuan to buy back 250,000 A-shares on May 8, 2024.
Kanglong Chemical (03759) spent 4.9874 million yuan to buy back 250,000 A shares on May 8
According to the Zhitong Finance App, Kanglong Chemical (03759) announced that on May 8, 2024, the company spent 4.9874 million yuan to repurchase 250,000 A shares, with a repurchase price of HK$19.92-19.99 per share.
Kanglong Chemical announced that it had not repurchased shares as of the end of April
Kanglong Chemical (03759) announced that during the period from April 26, 2024 to April 30, 2024 (a total of three trading days), the company did not repurchase shares. The company will then implement a share repurchase plan within the repurchase period according to market conditions, and promptly fulfill its information disclosure obligations in accordance with relevant laws and regulations. Investors are kindly requested to pay attention to investment risks.
Kanglong Chemical (300759.SZ): The company did not repurchase shares
Gelonghui, May 7, 丨 Kanglong Chemical (300759.SZ) announced that during the period from April 26, 2024 to April 30, 2024 (a total of three trading days), the company did not repurchase shares.
Trending Industry Today: WUXI BIO Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
May 6th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up, 1 constituents down and WUXI BIO leading
Direct impact of changes | Yao Ming Biotech rose more than 7% to lead CRO concept stocks. The Federal Reserve may still cut interest rates during the year, and overseas demand is expected to resume
On May 6, CRO concept stocks had the highest gains in early trading. As of press release, Tiger Pharmaceuticals (03347) rose 6.82% to HK$36.8; Pharmaceutical Biotech (02269) rose 5.87% to HK$36.45; Kanglong Chemical (03759) rose 4.92% to HK$10.44; and Pharmaceuticals Kangde (02359) rose 3.14% to HK$37.75.
Changes in Hong Kong stocks | CRO concept stocks fell across the board, Yakming Kangde (02359) fell more than 7%, leading the decline, and the company's profit margin for the first quarter fell short of expectations
CRO concept stocks fell across the board. As of press release, Yao Ming Kangde (02359) fell 6.47% to 36.15 yuan; Gloria Ying (06821) fell 5.33% to 63.05 yuan; Kanglong Chemical (03759) fell 4.96% to HK$9.96.
Kanglong Chemical (03759) plans to repurchase 200 million to 300 million yuan of A-shares
According to the Zhitong Finance App, Kang Long Huacheng (03759) announced that since the closing price of the company's A shares fell by more than 20% in 20 consecutive trading days as of April 19, 2024, necessary to protect the company's value and shareholders' rights and effectively promote the implementation of the “Double Improvement of Quality and Return” action plan, the company plans to use its own funds to repurchase some of the company's RMB common stock A shares through centralized bidding transactions. The total amount of capital for this repurchase is not less than RMB 200 million and no more than RMB 300 million (all inclusive), and the maximum repurchase price does not exceed
2023年度報告
Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
04:14 AM EDT, 04/29/2024 (MT Newswires) -- Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
Changes in Hong Kong stocks | CRO concept stocks continue to rebound, the downstream demand side needs to improve, and domestic CXO companies still have a competitive advantage
CRO concept stocks continued to rebound. As of press release, Viva Biotech (01873) rose 8.93% to HK$0.61; Kingsley Biotech (01548) rose 8.35% to HK$11.94; Kanglong Chemical (03759) rose 5.91% to HK$10.04; and Pharmaceutical Biotech (02269) rose 5.79% to HK$14.26.
Trending Industry Today: TIGERMED Leads Gains In Pharmaceutical Outsourcing/contract Research Organization(cro Concept) Stocks
April 26th - The industry of $Pharmaceutical Outsourcing/contract Research Organization(cro Concept)(BK1261.HK)$ is trending higher today with 8 constituents up and TIGERMED leading Gains.$TIGERMED(03
No Data